Jefferies raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $100 from $65 and keeps a Buy rating on the shares. The firm thinks azetukalner has the attributes of a top-selling epilepsy pill, driven by best-in-class focal epilepsy data. In 2026, Xenon shares could grind higher as Big Pharma interest rises and as the Street gauges azetuklaner’s peak sales potential, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals price target raised to $80 from $59 at RBC Capital
- Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate
- Xenon Pharmaceuticals: Blockbuster Potential for Azetukalner After Outperforming Phase 3 Epilepsy Data Drives Target Hike to $80
- Xenon Pharmaceuticals: Azetuklaner’s Strong Phase III Data and Blockbuster Potential Underscore Undervalued Buy Opportunity
- Xenon Pharmaceuticals price target raised to $97 from $63 at Baird